Is Cytomed Therapeutics Stock a good buy in 2024, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: GDTC) stock is to Buy GDTC stock.
Out of 1 analyst, 0 (0%) are recommending GDTC as a Strong Buy, 1 (100%) are recommending GDTC as a Buy, 0 (0%) are recommending GDTC as a Hold, 0 (0%) are recommending GDTC as a Sell, and 0 (0%) are recommending GDTC as a Strong Sell.
According to 1 Wall Street analyst that have issued a 1 year GDTC price target, the average GDTC price target is $5.00, with the highest GDTC stock price forecast at $5.00 and the lowest GDTC stock price forecast at $5.00.
The Wall Street analyst predicted that Cytomed Therapeutics's share price could reach $5.00 by Jun 11, 2025. The average Cytomed Therapeutics stock price prediction forecasts a potential upside of 138.66% from the current GDTC share price of $2.10.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.